OCTOBER 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA October 28. Selumetinib – PN NF1. The European Commission (EC) has approved the oral, selective MEK inhibitor for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1). NF1 is a rare, progressive, genetic condition that is caused by a spontaneous or inherited mutation in the NF1 Up […]